Premium
Imaging of human leukemic T‐Cell Xenografts in nude mice by radiolabeled monoclonal antibodies and F(ab') 2 fragments
Author(s) -
Vacca Angelo,
Mach JeanPierre,
Buchegger Franz,
Carrel Stefan
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880101)61:1<58::aid-cncr2820610111>3.0.co;2-i
Subject(s) - monoclonal antibody , jurkat cells , cd5 , microbiology and biotechnology , cell culture , antibody , antigen , medicine , t cell , lymphoma , pathology , cancer research , immunology , biology , immune system , genetics
Monoclonal antibodies (MoAb) that react with the T‐lymphocyte markers called cluster of differentiation CD5 and CD2 were labeled with iodine 131 ( 131 I) and were injected intravenously in nude mice bearing solid subcutaneous xenografts derived from the human T‐cell leukemia line Ichikawa. Both MoAb anti‐CD5 and anti‐CD2 yielded favorable mean tumor to whole‐body ratios of 3.8 and 5.1, respectively. These ratios were further increased up to 10.0 for MoAb anti‐CD5 and 15.5 for MoAb anti‐CD2 by using their F(ab') 2 fragments. The tumors could be imaged clearly by external scanning after injection of F(ab') 2 fragments from both MoAb. F(ab') 2 fragments from MoAb anti‐CD2 and of a third MoAb recognizing the clonotypic determinant (Ti) of the antigen receptor expressed by the human T‐cell line Jurkat were injected in mice bearing intrasplenic Jurkat xenografts. A selective localization of both fragments in tumor tissue was demonstrated with mean tumor to whole‐body ratios of 7.5 and 4.1 for MoAb anti‐CD2 and anti‐Ti, respectively. These in vivo experimental results may provide useful information for the potential use of radiolabeled MoAb and fragments in the diagnosis and treatment of patients with T‐cell lymphoma and different other forms of T‐cell malignancies.